BioSpace News Archive

Artelo Biosciences, Inc. announced that H.C. Wainwright will be hosting a virtual medical expert webinar on October 11, 2023 at 12:00 p.m. Eastern Time to discuss the current treatment landscape for cancer-related anorexia and cachexia.

China SXT Pharmaceuticals, Inc. today announced that its Board of Directors has set the date of October 5, 2023 to be the effective date for the Company’s one-for-twenty-five reverse stock split of its issued and outstanding ordinary shares.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) is pleased to announce a partnership with New York Cancer & Blood Specialists (NYCBS), a group of leading community cancer centers in the United States, to evaluate the Bria-IMT™ combination with a checkpoint inhibitor in its pivotal Phase 3 registration study in advanced breast cancer patients in New York.

Dimension Inx, a biomaterials platform company, today announced that CMFlex™, the first 3D-printed regenerative bone graft product with FDA approval, has been successfully used in its first clinical cases.

Today, Sanguina, Inc. (Sanguina), a leading biotech company, is pleased to announce the FDA clearance of AnemoCheck Home, the only FDA-cleared home hemoglobin test kit available in the United States.

Clarix Imaging, a medical technology company revolutionizing surgical oncology, announces $10 million in funding from kineo finance, a Swiss-headquartered investment firm.

ABM Respiratory Care, a medical technology company focused on developing and globally commercializing novel integrated airway clearance and ventilation solutions, is thrilled to announce a US exclusive distribution partnership with Mercury Medical for non-government acute care facilities.

Keros Therapeutics, Inc. today announced results from preclinical studies evaluating the treatment effect of a research form of KER-065 (“RKER-065”) in a mouse model of Duchenne muscular dystrophy (“DMD”) and in prednisolone-treated mice, which were presented at the 28th International Annual Congress of the World Muscle Society (“WMS”) on Wednesday, October 4, 2023.

Foghorn ® Therapeutics Inc. today announced that new clinical and pre-clinical data for its BRG1/BRM inhibitor FHD-286, pre-clinical data for its selective EP300 program, and pre-clinical data for its BRD9 degrader FHD-609, will be presented at the AACR-NCI-EORTC International Conference.

Daxor Corporation today announces it has been accepted into the National Institutes of Health (NIH) Catalyze Preclinical Services Program.